₹76.90
−7.35%NSE close, 16 Nov 2026
−20.48%
INVICTA DIAGNOSTIC is a small cap company, listed on NSE SME under the symbol INVICTA. At ₹76.90 a share, the market values the whole company at ₹97 crore. NSE SME is the exchange's platform for small and medium companies, which report their results every half year.
In FY26, it reported sales of ₹32 crore and a net profit of ₹5 crore, an operating margin of 30.2%.
The market values the company at 29.9 times its profit over the last twelve months and 1.68 times its book value; its return on equity is 5.6% and it has almost no borrowings.
Promoters hold 66.70% of the shares. Foreign institutions hold 1.54%, and domestic institutions, mutual funds among them, 4.25%.
Listed on NSE SME, the platform for small and medium companies: its shares trade in large lots and often thinly, so the price can move sharply on a few trades, and companies file results every half year.
₹ crore. Consolidated figures.
| Line | 6M to Mar 2026 | 6M to Sep 2026 |
|---|---|---|
| Sales | 15.4 | 24.3 |
| Expenses | 12.4 | 17.4 |
| Operating profit | 3.0 | 6.9 |
| Operating margin | 19.5% | 28.4% |
| Other income | 0.6 | 0.5 |
| Interest | 0.1 | 0.1 |
| Depreciation | 1.9 | 2.8 |
| Profit before tax |
The financial results for the period ended September 30, 2026.
The financial results for the period ended September 30, 2026.
A copy Srutinizers report of Annual General Meeting held on September 19, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 19, 2026
Outcome of Board Meeting held on September 18, 2026 wherein Board considered and approved the proposed business outlook and forward-looking guidance to be communicated by the Chairman & Managing Director and Chief Financial Officer to the Members at the Company s 3rd Annual…
| 4.4 |
| Tax | 0.8 | 1.9 |
|---|
| Net profit | 0.9 | 2.3 |
|---|
| EPS (₹) | 0.79 | 2.01 |
|---|
₹ crore, financial years to March.
| Line | FY26 |
|---|---|
| Sales | 32.4 |
| Expenses | 22.6 |
| Operating profit | 9.8 |
| Operating margin | 30.2% |
| Other income | 0.7 |
| Interest | 0.2 |
| Depreciation | 3.3 |
| Profit before tax | 7.0 |
| Tax | 2.1 |
| Net profit | 4.9 |
| EPS (₹) | 4.90 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY26 | 6M to Sep 2026 |
|---|---|---|
| From operations | 2.9 | 9.3 |
| From investing | −13.7 | −19.7 |
| From financing | 30.8 | 2.4 |
| Spent on fixed assets | −13.0 | −14.1 |
| Free cash flow | −10.0 | −4.7 |
Margins, returns, debt, tax and cash.
| Line | FY26 |
|---|---|
| Net margin | 15.2% |
| Operating margin | 30.2% |
| Return on equity | 9.8% |
| Return on capital employed | 13.5% |
| Return on assets | 8.2% |
| Debt to equity | 0.07 |
| Interest coverage | 36.10 |
| Debt to assets | 0.06 |
| Current ratio | 4.79 |
| Quick ratio | 4.71 |
| Cash ratio | 3.10 |
| Asset turnover | 0.54 |
| Fixed asset turnover | 1.69 |
| Inventory turnover | 4.60 |
| Receivables turnover | 56.80 |
| Gross margin | 91.6% |
| Cash from operations to profit | 60.0% |
| Effective tax rate | 30.5% |
Commencement of commercial operations of Centres at Shegaon Diagnostic LLP (a Subsidiary LLP), and Porteus Pathogenius LLP (a Step-Down Subsidiary LLP)
Notice of 3rd Annual General Meeting to be held on September 19, 2026
Outcome of Board Meeting held on August 25, 2026.
Outcome of Board Meeting held on July 29, 2026. Board at its meeting held today1. The Board took on record and accepted the resignation of Mr. Rohit Prakash Srivastava (DIN: 01432112) from the office of Whole-time Director (Finance) and Director of the Company2. The Board…
Change in Director(s) of the company.
Change in Management of Porteus Pathogenius LLP, a subsidiary of Porteus Medical LLP, which is a subsidiary of Invicta Diagnostic Limited
Invicta Diagnostic Limited Starts Commercial Operations at Pune Centre; Total Network Reaches 10 Diagnostic Centres
Company's Subsidiary LLP i.e. Porteus Medical LLP has established its diagnostic services centre at Pune Centre and it has started commercial operations on 30 June, 2026
Porteus Medical LLP a subsidiary LLP of the Company, has incorporated a Limited Liability Partnership namely Porteus Pathogenius LLP and Consequent to the above incorporation, Porteus Pathogenius LLP has become a Step-Down Subsidiary of the Company. Further the Initial LLP…